Sells topical medicines for psoriasis, atopic dermatitis, and seborrheic dermatitis through healthcare providers to patients.
10-K for FY2025, filed Feb 25, 2026We launched our lead product, ZORYVE cream 0.3%, in August 2022 after obtaining our initial FDA approval for the treatment of plaque…View ↗
In December 2023, we received FDA approval for ZORYVE foam 0.3% for the treatment of seborrheic dermatitis in individuals aged 9 years and…View ↗
We also received FDA approval for, and commercially launched, ZORYVE cream 0.15% in July 2024 for the topical treatment of mild to moderate…View ↗
The Company sells its product to its customers in the United States and Canada. The Company’s customers subsequently resell the products to…View ↗
Most revenue comes from product sales to customers in the United States and Canada, counted when the products are delivered; other revenue primarily comes from licensing agreements.
10-K for FY2025, filed Feb 25, 2026The Company sells its product to its customers in the United States and Canada. The Company’s customers subsequently resell the products to…View ↗
Company’s products, which typically occurs upon delivery to the customer. The Company’s payment terms are generally between 30 - 65 days.View ↗
Year Ended December 31, 2025 2024 2023 ZORYVE cream 0.3% $ 120,995 $ 85,082 $ 29,186 ZORYVE foam 181,892 71,539 — ZORYVE cream 0.15% 68,274…View ↗
Other revenue relates primarily to the Sato and Huadong licensing agreements. See Note 7.View ↗
10-K for FY2025, filed Feb 25, 2026
FY2025 revenue by product or service (Product revenue, net) ↗$376.1M
10-K for FY2025, filed Feb 25, 2026
$376.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
ZORYVE cream 0.3%
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
33%
FY2022: 100%
|
ZORYVE cream 0.3%, FY2025
$121M Sources
|
Sold outright |
|
ZORYVE foam
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
49%
FY2022: 0.0%
|
ZORYVE foam, FY2025
$181.9M Sources
|
Sold outright |
|
ZORYVE cream 0.15%
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
18%
FY2022: 0.0%
|
ZORYVE cream 0.15%, FY2025
$68.3M Sources
|
Sold outright |
|
ZORYVE cream 0.05%
Sold outright
|
0.2% |
ZORYVE cream 0.05%, FY2025
$911K Sources
|
Sold outright |
Arcutis sells to wholesalers and specialty pharmacies in the United States and Canada, which resell its products to pharmacies, healthcare providers, and patients.
10-K for FY2025, filed Feb 25, 2026
No. It lost $16.1M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Aug 5, 2026
Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23%…View ↗
More products reached the market
ZORYVE expanded from a psoriasis cream to include commercially launched foam and atopic-dermatitis creams; the older report described the foam and atopic-dermatitis cream as still in development.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 25, 2026
Competes with AbbVie, UCB, Amgen, Bristol Myers Squibb, Organon, Galderma Laboratories, Biocon, Johnson & Johnson, Protagonist Therapeutics, Meiji Pharma, UNION, Pfizer, Incyte, Arcotech, LEO Pharma, Sanofi, Regeneron Pharmaceuticals, Eli Lilly and, Apogee Therapeutics, and Nektar Therapeutics
10-K for FY2025, filed Feb 25, 2026injected biologic therapies such as Skyrizi®, marketed by AbbVie Inc., and Bimzelex®, marketed by UCB, Inc.; non-injectable systemic…View ↗
Loading...